Company intelligence / Profile preview

NewLimit

South San Francisco, California, United Statesnewlimit.com ↗

Ownership: Private
Development stage: Other

Overview

NewLimit has developed an mRNA-based therapeutic delivered via lipid nanoparticles targeting hepatocytes in the liver. Their lead program aims to restore youthful function in aged liver cells by delivering transcription factors that reset epigenetic age. The company has completed large-scale screens in human T cells and improved its delivery technology over time. No clinical results yet; first-in-human trials are planned within a few years, starting with alcohol-related liver disease as an initial indication before expanding to broader metabolic and age-associated conditions.

Therapeutic areas: GastroenterologyMetabolic Disorders
Modalities: mRNA-based drugsLipid nanoparticle delivery therapyEpigenetic reprogramming therapy
Industry: Biotech

Beyond the preview

Go deeper on NewLimit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NewLimit.

Explore the full profile